MediWound Ltd.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.0M | $20.2M | $18.7M | $26.5M | $23.8M | $21.8M | $31.8M | $3.4M |
| Cost of Revenue | $13.7M | $17.6M | $15.1M | $13.3M | $15.0M | $14.2M | $11.8M | $2.1M |
| Gross Profit | $3.3M | $2.6M | $3.6M | $13.2M | $8.8M | $7.5M | $19.9M | $1.3M |
| Gross Margin | 19.2% | 13.0% | 19.1% | 49.7% | 36.9% | 34.7% | 62.7% | 38.6% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | — | — | — | — | — | — | — |
| Operating Income | $-25.3M | $-19.4M | $-15.3M | $-8.3M | $-11.2M | $-8.8M | $4.5M | $-4.0M |
| Operating Margin | -149.0% | -95.9% | -81.8% | -31.5% | -47.2% | -40.6% | 14.1% | -116.4% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-23.7M | $-30.2M | $-6.5M | $-19.5M | $-13.5M | $-9.3M | $2.1M | — |
| Income Tax Expense | $169.0K | $61.0K | $185.0K | $78.0K | $27.0K | $0 | $0 | — |
| Net Income | $-23.9M | $-30.2M | $-6.7M | $-19.6M | $-13.6M | $-9.2M | $5.0M | $-1.1M |
| Net Margin | -140.8% | -149.5% | -35.9% | -74.0% | -57.0% | -42.3% | 15.6% | -31.1% |
| EPS (Basic) | $-2.10 | $-3.03 | $-0.75 | $-3.93 | $-3.48 | $-2.38 | — | — |
| EPS (Diluted) | $-2.10 | $-3.03 | $-0.75 | $-3.93 | $-3.48 | $-2.38 | — | — |
| Shares Outstanding (Basic) | 12.8M | 10.8M | 9.2M | 7.2M | 27.3M | 27.2M | 27.2M | 27.2M |
| Shares Outstanding (Diluted) | 12.8M | 10.8M | 9.2M | 7.2M | 27.3M | 27.2M | 27.2M | 27.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |